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Objective: The increasing use of aortic endografts predictably will add to the complexity of open abdominal aortic
aneurysm (AAA) repair and, therefore, the proportion of surgically treated infrarenal AAAs that are juxtarenal in location
(JRA) will grow. This study reviews a single-center experience with JRAs.
Methods: Between June 1994 and December 2000, 138 patients underwent elective repair of a JRA, comprising 16.1% of
859 consecutive asymptomatic and intact symptomatic nonruptured infrarenal AAAs repaired over the same period. All
patients with JRA needed proximal suprarenal clamping (SRC) or supravisceral (SVC) clamping. Patient demographics,
selected risk factors, and operative details were recorded. Univariate analyses of selected risk factors for an adverse
perioperative event were assessed, and multivariate analyses were performed with linear and logistic regression with
backwards selection.
Results: SRC was used in 95 patients (69%), and 43 patients (31%) underwent SVC. The mortality rate was 5.1% (7/138)
for JRA repair, and 2.8% (20/720) for infrarenal AAA repair (P  .03). The mortality rate was significantly greater for
those patients who received SVC compared with SRC (11.6% versus 2.1%; P .02). Multivariate analysis identified SVC
position as the only independent predictor of mortality (odds ratio [OR], 6.1; 95% CI, 1.1 to 32.9; P .035). Transient
renal insufficiency occurred in 39 patients (28.3%), but only eight patients (5.8%) needed dialysis. Patients who had SVC
had a significantly greater rate of renal insufficiency than those who received SRC (41.9% versus 22.1%; P  .02).
Multivariate analysis showed SVC position (OR, 3.3; 95% CI, 1.4 to 7.8; P  .008), diabetes (OR, 3.7; 95% CI, 1.1 to
12.9; P .04), and preoperative renal insufficiency (OR, 5.8; 95% CI, 2.2 to 15.4; P < .001) were independent predictors
of postoperative renal insufficiency. Renal ischemia during proximal clamping cannot alone explain renal complications
because clamp time was shorter in patients with SVC (24.9  2.4 minutes versus 32.2  1.5 minutes; P  .009).
Conclusion: JRA repair can be accomplished with a low mortality rate, but a more proximal clamp position may adversely
affect outcome in these patients. Postoperative renal insufficiency is related to diabetes, preoperative renal insufficiency,
and SVC position. These results suggest SRC is safer than SVC for proximal aortic clamp control of JRAs. Although
clamp level must be tailored to patient anatomy, outcome may be improved if the clamp level can be kept distal to the
superior mesenteric artery origin. (J Vasc Surg 2002;36:1104-11.)
The technical details of juxtarenal abdominal aortic
aneurysm (JRA) repair require operative strategies that are
more complex than routine infrarenal abdominal aortic
aneurysm (AAA) repair. The potential deleterious effects of
both suprarenal and supravisceral aortic cross clamping
have previously been elucidated and include ischemic ne-
phropathy,1 visceral ischemia/reperfusion injury,2 emboli-
zation, and coagulation disorders.3 Some authors have
advocated different approaches to facilitate a safer repair,
such as retroperitoneal exposure,4,5 or routine supraceliac
cross clamping6 to avoid dissection and clamping around
the renal arteries.
Combined results for both conventional open surgical
suprarenal and JRA repairs previously have been report-
ed,7-9 and our own results for suprarenal AAA repair have
been reported as part of a large thoracoabdominal aneu-
rysm series.10 However, few reports specifically analyze
outcome data from infrarenal AAAs that are juxtarenal in
location and require supravisceral or suprarenal cross
clamping. With an increasing number of infrarenal AAAs
being repaired with endoluminal stent grafts, the next
hurdle will be to perfect JRA repair through minimally
invasive techniques. We sought to evaluate our results with
suprarenal clamping (SRC) and supravisceral (SVC) aortic
clamping for JRA repair, to compare different clamp loca-
tions, to identify factors predictive of outcome, and to
provide baseline data for future stent graft comparisons.
METHODS
From June 1, 1994, to December 31, 2000, all patients
who underwent infrarenal AAA repair by members of our
department were prospectively entered into a computer-
ized database. This study had approval of our institutional
review board. Operative notes were reviewed for cross-
clamp location, and data then were gathered through re-
view of the medical record. An aneurysm was considered
juxtarenal if it encroached on the renal arteries (but did not
include the renal arteries), had no suitable neck for clamp-
ing, and required either a suprarenal or supravisceral cross
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clamp for proximal control. Excluded were type IV thora-
coabdominal aneurysms, suprarenal/pararenal aneurysms,
patients with polar renal arteries, and ruptured aortic aneu-
rysms. Aneurysms were evaluated with computed tomo-
graphic or magnetic resonance imaging scans and aortic
angiography.
A total of 859 consecutive open surgical procedures
were performed to repair infrarenal AAAs during this pe-
riod. One hundred thirty-eight patients (16.1%) needed
SVC or SRC and serve as the study group, of which 17
(12.3%) were symptomatic and 121 (87.7%) were asymp-
tomatic. One hundred twenty-five of the aneurysms
(90.6%) were degenerative/atherosclerotic aneurysms, and
13 (9.4%) were inflammatory aneurysms. All patients re-
ceived intraoperative heparin; mannitol, furosemide, and
low-dose dopamine were routinely used for renal protec-
tion.
Outcome assessment and statistical methods. Pa-
tient demographics analyzed were age, gender, size of
aneurysm, coronary artery disease (CAD), previous coro-
nary artery bypass or percutaneous coronary angioplasty,
history of chronic obstructive pulmonary disease (COPD),
renal failure, hypertension, diabetes, and symptoms related
to the aneurysm. The intraoperative details reviewed were:
clamp location, clamp time, concurrent renal artery endar-
terectomy or bypass, type of repair (aortobiiliac, aortob-
ifemoral, or tube graft), surgeon, and exposure (retroperi-
toneal versus transabdominal).
The primary outcome measurements analyzed were:
in-hospital or 30-day mortality, postoperative renal insuffi-
ciency, dialysis dependence, myocardial infarction, pulmo-
nary failure, return of bowel function, blood products
transfused (total products, packed red blood cells [pRBCs],
fresh frozen plasma [FFP], and platelets), hospital length of
stay, and intensive care unit (ICU) length of stay. Compli-
cations are reported according to previously established
guidelines.11 Renal insufficiency was considered if any post-
operative creatinine level was greater than 1.8 mg/dL or, in
the case of underlying renal insufficiency, a 50% increase
above the patient’s preoperative baseline. Only one patient
was on dialysis before surgery. A compilation of total pul-
monary complications included prolonged postoperative
intubation period (48 hours), the need for reintubation,
or positive sputum culture and radiographically confirmed
pneumonia. Myocardial infarction was defined as an eleva-
tion of creatinine phosphokinase or troponin I levels and
concomitant electrocardiographic changes.
Waldon’s 2 test and Fisher exact test were used to
assess the association between clamp type and preoperative,
intraoperative, and postoperative categoric variables. Wil-
coxon rank sum test and unequal variances t test were used
to assess the univariate association between clamp type and
preoperative, intraoperative, and postoperative continuous
variables. Logistic and linear multivariate regression models
with backwards selection were used to assess the association
between selected risk factors and outcomes, adjusting for
possible confounders amoung the preoperative and intra-
operative variables. Continuous outcomes were log trans-
formed to better meet model assumptions.12 All tests were
performed at a significance level of .05 with SAS 8 software
(SAS Institute, Cary, NC).
RESULTS
The average number of JRAs performed each year was
21.2 (16%); however, the number of patients who needed
SVC or SRC as a proportion of total open surgical infrare-
nal aneurysm repairs steadily increased over this period
from 10.8% in 1995 to 31.7% in 2000. Of the JRAs
reported in this series, 56% were repaired with aortic tube
grafts, 42% with aortobiiliac grafts, and 2% with aortob-
ifemoral grafts. Baseline demographics for SVC and SRC
are summarized in Tables I and II. No difference was seen
between the groups with respect to age, size of the aneu-
rysm, gender, history of CAD, previous coronary interven-
tion (coronary artery bypass or percutaneous coronary an-
gioplasty), diabetes, hypertension, COPD, preoperative
renal insufficiency, or aneurysm symptoms.
No difference was seen between groups with respect to
operative exposure (retroperitoneal approach, 57.6%; ver-
sus transabdominal approach, 42.4%; P  .69). A total of
26.8% of JRAs repaired underwent a combined renal artery
procedure. Thirty-five percent of patients who had SVC
underwent a combined renal artery procedure, compared
with 23.2% of those who had SRC, but this did not reach
statistical significance (P  .16). Despite a greater number
of simultaneous renal artery procedures, the average clamp
time in patients who received SVC was 24.9 2.4 minutes,
which was significantly less than the 32.3 1.5 minutes in
those who received SRC (P  .009).
In-hospital outcome data are provided in Table III. No
difference was seen between groups with respect to hospital
length of stay, ICU length of stay, return of bowel function,
total blood products transfused, and pRBCs transfused.
The median number of units of FFP and platelets trans-
fused were significantly greater in those patients who re-
ceived a SVC compared with SRC.
Complications are depicted in the Fig. No difference
was seen between groups with respect to pulmonary com-
plications, incidence of dialysis dependence, and myocar-
dial infarction. The overall incidence rate of renal insuffi-
ciency was 27.5%. Patients who received a SVC were more
likely to have postoperative renal insufficiency compared
with those who received SRC (41.9% versus 22.1%). The
overall mortality rate was 5.1%, with a significantly greater
rate in patients with SVC (11.6%) compared with patients
with SRC (2.1%). No intraoperative deaths occurred. Four
Table I. Demographic data
SVC SRC P value
No. 138 43 (31%) 95 (69%)
Age* (y) 71.7  0.6 72.3  7.9 71.4  6.9 .52
Aneurysm
size* (cm)
6.4  0.1 6.6  1.3 6.4  1.3 .39
*Mean  standard error.
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patients died of multisystem organ failure, three of whom
received a SVC and one a SRC. Two patients died of
mesenteric ischemia, and both received a SVC. The other
death in the SRC group was from a ventricular arrhythmia.
The mortality rate for symptomatic patients was 5.9% and
for those who underwent a renal artery repair was 8.1%.
Three patients returned to the operating room for a
bleeding complication, two in the SVC group (4.6%) and
one in the SRC group (1.1%). One patient in each group
needed reoperation for a lower extremity embolic event.
Three patients in each group had pancreatitis develop, and
five patients in the SVC group and four in the SRC group
had elevation of hepatic serum transaminase to greater than
two times normal.
Multivariate analyses with linear and logistic regression
were performed to further clarify the independence of
categoric and continuous factors as predictors of outcomes.
The results of these analyses are provided in Table IV as
odds ratio (OR) with 95% CI. The only significant predic-
tor of postoperative mortality with logistic regression was
the use of SVC (OR, 6.1; 95% CI, 1.1 to 32.9). SVC (OR,
3.3; 95% CI, 1.4 to 7.8), the presence of diabetes (OR, 3.7;
95% CI, 1.1 to 12.9), and preoperative renal insufficiency
(OR, 5.8; 95% CI, 2.2 to 15.4) were all predictors of
postoperative renal insufficiency, but no identifiable vari-
able predicted postoperative dialysis dependence.
Patients who were advanced in age greater than 70
years (OR, 1.2; 95% CI, 1.1 to 2.0), patients who had a
history of COPD (OR, 1.4; 95% CI, 1.1 to 2.0), and those
who had preoperative renal insufficiency (OR, 1.4; 95% CI,
1.1 to 1.8) had an increased likelihood with linear regres-
sion of receiving multiple blood products. Patients who
were advanced in age greater than 70 years (OR, 1.2; 95%
CI, 1.1 to 2.0), who had COPD (OR, 1.5; 95% CI, 1.1 to
2.0), or who had preoperative renal insufficiency (OR, 1.4;
95% CI, 1.1 to 1.8) were also more likely to receive pRBCs.
If symptoms were present, a patient was more likely to have
a longer length of stay (OR, 1.5; 95% CI, 1.1 to 1.8), but
no significant association was seen between factors analyzed
and ICU length of stay, postoperative pulmonary failure,
myocardial infarction, or return of bowel function.
DISCUSSION
At present, 60% of infrarenal AAAs are estimated to be
candidates for repair with an endovascular stent graft, and
therefore, the percentage of JRAs repaired with open tech-
niques will increase.13 Our data support this as the percent-
age of JRAs repaired at the Cleveland Clinic in 1995 was
10.8% but in 2000 rose to 31.7%. The predominant limi-
tations that preclude implantation of an endograft are the
size of the proximal neck and the location of the aneurysm
with respect to the renal arteries. However, several new
devices make endovascular repair of JRA and suprarenal
aneurysms feasible and are under clinical investigation. We
sought to review our open results to set a benchmark for
comparison of future endovascular grafts. In addition, we
evaluated comorbidities and intraoperative details to iden-
tify factors predictive of outcome.
Table II. Baseline variables in SVC and SRC groups undergoing AAA repair
Total Percent SVC Percent SRC Percent P value
Gender Women 46 33.0% 15 35.7% 31 33.0% .76
Men 92 67.0% 28 64.3% 64 67.0%
CAD No 44 31.9% 12 27.9% 32 33.7% .50
Yes 94 68.1% 31 72.1% 63 66.3%
Previous
CABG/
PTCA
No 75 54.3% 26 60.5% 49 51.6% .33
Yes 63 45.7% 17 39.5% 46 48.4%
COPD No 83 60.1% 27 62.8% 56 59.0% .67
Yes 55 39.9% 16 37.2% 39 41.0%
Renal
(Cr  1.8)
No 111 80.4% 37 86.1% 74 77.9% .25
Yes 27 19.6% 6 14.0% 21 22.1%
Symptoms No 121 87.7% 40 93.0% 81 85.3% .18
Yes 17 12.3% 3 7.0% 14 14.7%
Diabetes No 124 89/9 37 86.1% 87 91.6% .27
Yes 14 9.1% 6 14.9% 8 8.4%
Hypertension No 37 26.8% 12 27.9% 25 26.3% .85
Yes 101 73.2% 31 72.1% 70 73.7%
CABG, Coronary artery bypass; PTCA, percutaneous coronary angioplasty; Cr, creatinine level.
Table III. Continuous outcomes in patients with JRA
*Overall *SVC *SRC P value
Length of stay 8 (7, 12) 8 (6, 11) 8 (7, 12) .52
ICU length of stay 3 (2, 4) 3 (2, 5) 3 (2, 4) .68
Bowel function 4 (3, 5) 4 (3, 7) 4 (3, 5) .94
Packed cells 3 (2, 6) 3 (2, 8) 3 (2, 5) .17
Plasma 0 (0, 2) 1 (0, 4) 0 (0, 2) .04
Platelets 0 (0, 1) 1 (0, 2) 0 (0, 1) .04
Total products 5 (3, 10) 5 (3, 4) 4 (2, 9) .17
*Median (25%, 75%).
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The mortality rate for routine infrarenal AAA repairs
performed at the Cleveland Clinic has been reported to be
1.2%,14 with part of the period for this report overlapping
that study. However, included in this paper are patients
with symptomatic aneurysms and concomitant renal artery
revascularization, both of which have expected higher com-
plication rates. In addition, we also recently have docu-
mented similarly low mortality rates for endovascular AAA
repair.15 Mortality rates for suprarenal AAA repair have
been reported to be higher than for infrarenal AAA re-
pair,6,7,10,16 likely because of the increased complexity of
the repair in addition to the sequela of visceral organ
ischemia and reperfusion. The JRA repair mortality rate
reported in this article was significantly greater than the
infrarenal AAA repair mortality rate (5.1% versus 2.8%);
however, no difference was seen in mortality rate if one
considers only those patients who had a SRC (2.1%). Sev-
eral factors contribute to the aforementioned differences,
including cross-clamp time, clamp location, and emboliza-
tion. Of all the factors analyzed in this cohort, only clamp
location (SVC) turned out to be a significant predictor of
mortality. These results are similar to those reported by the
San Francisco group,7 but different than reported by Green
et al.6 In Green’s study, the mortality rate for JRA was
15.3%. However, their results are skewed by the fact that
most of the SRC difficulties were in those patients who
initially had an infrarenal clamp, which was abandoned for
a SRC when intraoperative difficulties were encountered.
We did have one patient with a similar fate in our series,
with an infrarenal clamp abandoned for a SVC after diffi-
culty with the proximal neck was encountered.
This article has the inherent drawbacks of a retrospec-
tive review. As such, a selection bias undoubtedly exists
between where to place the proximal clamp, and therefore,
patients with more difficult aortic anatomy were more likely
to receive a SVC. In addition, because this study is retro-
spective in nature, we can only speculate why SVC has a
higher mortality rate than routine infrarenal AAA repair.
One possible explanation may be from referral patterns
because 65% of our patients had underlying CAD, which is
Table IV. Multivariate analyses of outcome (logistic and linear regression)
Outcome Variable OR P value
Mortality Supravisceral clamp 6.1 (1.1,32.9) .035
Postoperative renal insufficiency Supravisceral clamp 3.3 (1.4, 7.8) .008
Diabetes 3.7 (1.1,12.9) .040
Preoperative renal failure 5.8 (2.2,15.4) .001
Total blood products Supravisceral clamp 1.3 (1.0, 1.8) .084
Age 1.3 (1.0, 1.6) .024
Preoperative renal failure 1.5 (1.0, 2.2) .04
pRBCs Supravisceral clamp 1.3 (1.0, 1.6) .078
Age 1.2 (1.1, 2.0) .055
COPD 1.5 (1.1, 2.0) .015
Preoperative renal failure 1.4 (1.1, 1.8) .017
Length of stay Supravisceral clamp 1.0 (0.8, 1.1) .52
Symptoms 1.5 (1.1, 1.8) .002
Categoric outcomes (complications) in patients with JRA. MI, Myocardial infarction; Pulm, pulmonary. *P  .05.
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much higher than other large series of JRA.7,8,17 However,
neither history of CAD or coronary revascularization
turned out to be significant predictor of mortality in this
report, as only one death was directly attributed to coronary
disease (ventricular arrhythmia). The adverse sequelae of
visceral ischemia and reperfusion injury have been reported
to increase with clamp times greater than 40 minutes18
after thoracoabdominal aneurysm repair, but our clamp
times on average were well under this period and were in
fact were lower in the SVC group. Three of the five deaths
in the SVC group were from multisystem organ failure,
with two of the three resulting directly from mesenteric
ischemia and the etiology speculated to be microembolic in
nature. Huber et al19 previously reported that multisystem
organ failure is the most common etiology of death after
infrarenal AAA repair, but when SVC and SRC are used,
this likely is the result of a complex cascade of events.
Seventy-one percent of the patients who died (5/7) had
dialysis-dependent renal failure develop, which has previ-
ously been associated with increased mortality after SVC.20
The ensuing coagulopathy that results from visceral isch-
emia has been well documented,21 and two of the five who
died in the SVC group needed reoperation for bleeding.
Certainly, not every patient with a JRA is a candidate
for SRC, as clamp location is often dictated by the amount
of perirenal atherosclerosis or thrombus, in addition to the
proximity of the superior mesenteric artery to the renal
arteries. However, the data presented here support the
preferential use of SRC, if technically feasible, as a safe
method for proximal aortic control for JRAs. The greater
number of cross clamps placed just above the renal arteries
(compared with above the mesenteric vessels) in this series
has undoubtedly been facilitated by advances in imaging
techniques. Over the past two decades, tremendous im-
provement has been seen in computerized tomography
resolution and in obtaining noncontrast and contrast-en-
hanced computerized tomographic scans to ascertain the
degree of calcification and thrombus in the perivisceral
aorta. In addition, the routine use of preoperative angiog-
raphy and the results of other reports6,7 have persuaded us
to clamp above either the renal arteries or visceral arteries
primarily and sooner when a difficult proximal neck is
suspected.
Our rates of transient renal insufficiency were much
higher than expected but are similar to the results presented
in our TAA series10 and other large-center series of
JRA.6,7,17 The percentage of patients in whom permanent
postoperative dialysis dependence developed was 5.8%,
which is also similar to other large series of JRA. The
etiology of the renal failure is likely multifactorial as the
duration of ischemic nephropathy could not alone explain
the degree of renal insufficiency because the average clamp
time was longer in those patients who had a SRC compared
with SVC. Multivariate analysis in this report found that
SVC, preoperative renal insufficency, and diabetes were all
predictive of postopertaive renal insufficiency. That there
was an increased likelihood of transient renal insufficiency
in patients with underlying renal insufficiency or diabetes
mellitus is not surprising. The causative factors for the
increased incidence rate of renal insufficiency in patients
with a SVC compared with SRC is not known; it is possible
that in addition to ischemic nephropathy, atheroembolism
or cytokine-mediated events from visceral ischemia/reper-
fusion may play a role.
No single factor in the mutifactorial analysis was iden-
tified to be associated with dialysis dependence, and no
difference was seen between SRC and SVC for dialysis
dependence. Our use of renal perfusate was variable and, in
general, was used liberally when longer clamp times and
renal revascularization were anticipated. The total number
of combined renal artery procedures was 27%, with more
patients in the SVC group (35% versus 23%) than the SRC
group undergoing combined renal artery revascularization.
This did not reach statistical significance and was not sig-
nificant in the multifactorial model. Although the signifi-
cance of adding renal revascularization procedures did not
reach significance in our model, we have previously re-
ported higher mortality rates and dialysis-dependant renal
failure in patients who undergo renal artery revasculariza-
tion in conjunction with aortic replacement.22 Our prefer-
ences for renal revascularization combined with aortic re-
placement are to perform renal artery endarterectomy or
bypass if the patient has uncontrollable hypertension on
three or more medications, has a preocclusive lesion, or has
ischemic nephropathy with a kidney size greater than 7 cm.
Although we did not measure specific coagulation pro-
files, the median units of blood products transfused and
pRBCs transfused were not different for clamp location.
However, SVC approached significance as a predictor of
total products (P  .17, univariate analysis; P  .084,
multivariate analysis) and pRBCs transfused (P  .17,
univariate analysis; P .078, multivariate analysis). Preop-
erative renal insufficiency was a predictor of increased total
products and pRBCs transfused, with the suspected mech-
anism from uremic platelet dysfunction. The median num-
ber of platelets and FFP transfused was significantly higher
in patients who received a SVC, but this did not turn out to
be significant in the multifactorial model. The effects of
SVC on the coagulation cascade have been studied exten-
sively, with the resultant coagulopathy assumed to be sec-
ondary to enhanced primary fibrinolysis from decreased
degradation of tissue plasminogen activator21 or excessive
consumption of procoagulant factors.3 In addition, there
was the need for increased transfusion of platelets and FFP
in this cohort. Two of the patients in the SVC group who
had a significant postoperative hemorrhage necessitating
reoperation died. Unquestionably, if one can avoid the
coagulopathic sequela of SVC, bleeding complications may
be prevented.
In conclusion, contemporary open surgical infrarenal
AAA repairs are more frequently juxtarenal in location.
Although the mortality rate remains low, improved out-
comes for both mortality and renal insufficiency may be
facilitated with careful selection of clamp location, which is
dictated by the anatomy in both the suprarenal and supra-
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visceral aortic segments. When a suprarenal clamp is possi-
ble, outcome may be improved over that after SVC.
We thank Becky Roberts who maintains our depart-
ment registry database and Edwin Beven, MD, who con-
tributed many patients to this study before his retirement in
1999.
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DISCUSSION
Dr John J. Ricotta (Stony Brook, NY). This is a very nice
paper from the Cleveland Clinic group with excellent results in a
very difficult group of patients.
Intuitively, this does not make a lot of sense to me, so I am
trying to figure out what the issues were here. And I think one of
the problems is when you only have eight mortalities, which is
wonderful, it is very difficult to tell what is going on between the
groups. So, you may have some issues that do not come through in
your analysis. It is hard for me to believe that with the short clamp
times you have here that you should see the differences that you
do. So, I wanted to ask you a couple of questions.
One was how you decided where to put the clamp? And the
reason I am asking you this is sometimes the character of the
visceral aorta, even though it is a perirenal aneurysm or a juxtarenal
aneurysm, the character of the visceral aorta may be different.
There may be thrombus. There may be degenerated atheroma in
the visceral aorta. And it may be that the people in whom you put
the supraceliac clamp in had a more diseased aorta in the visceral
segment than the patients that you put the suprarenal clamp. So, I
would ask you whether you have an idea about that?
The second thing you have addressed indirectly in terms of
blood product requirements, but did you measure the blood loss?
Do you know whether there was a difference in blood loss between
the suprarenal clamp and the supraceliac clamp? And do you know
whether there was increased hypotension or any sort of hemody-
namic change that might explain some of either your mortality or
your morbidity? There is a suggestion, again, that there was more
coagulopathy in the supraceliac clamp. Again, though, your clamp
times were not terribly long, so it may be just those specific
patients.
Was the retroperitoneal approach, when it was used, was that
a matter of physician preference?
And the final question that I have is whether you would
consider using a combination of open/endovascular approaches.
We just had a patient, who is 85 years old, with an aneurysm like
this, and the strategy has been to do hepatorenal and splenorenal
bypasses first and then put an endograft in using that neck. So, have
you had any experience or would you comment on whether you
think that might be a reasonable thing to do?
Dr Timur P. Sarac. Thank you for your kind comments, Dr
Ricotta.
When you ask the question, how is it decided where to put the
clamp, this has evolved over time. The initial impetus for reviewing
clamp location came from the Rochester series published in the late
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1980s, for which Dr Ricotta was a leading author. In that paper, it
was recommended that all juxtarenal aneurysms have their clamp
location placed above the celiac artery. However, the practice
patterns at the Cleveland Clinic have been different. We preferen-
tially place the proximal aortic clamp above the renal arteries if we
encounter a juxtarenal aneurysm that cannot accomadate an infra-
renal clamp. The decision making has been augmented by the
introduction of endovascular stent grafts, where we are now rou-
tinely get 3-mm cuts on our CAT scans, which gives us a much
better picture of the paravisceral aorta and whether there is extreme
calcification or thrombus. In those scenarios, we would be more
apt to place the proximal clamp at the supraceliac level. In addition,
we now routinely get noncontrast-enhanced CAT scans, which
gives us a very good picture of the degree of calcification in that
region. With the evolution of CAT scan and dynamic CAT scans
over the past 10 years, it really has been a great benefit in providing
the clarity of what the aorta looks like in that area.
In addition, one of the most important points that came out of
the Rochester study was the routine use of angiograms in patients
with juxtarenal aneurysm. Again, this helps us determine if it is
unsafe to place a suprarenal clamp and therefore immmediately go
to the supraceliac aorta.
Finally, because of previous results published in the literature
in the late 1980s, we now are more likely to clamp above the renals
or the supraceliac aorta if it is at all suspected there is going to be
some difficulty. So, we will not place a clamp on an infrarenal aorta
and are more likely to move the clamp higher earlier with resultant
sequela known from visceral ischemia-reperfusion, but keeping
ourselves out of technical trouble within the operating room.
As far as explaining the differences in results and low mortality
rates, my senior partners should be commended. Since this is a
retrospective study, I can only speculate on theories and extrapo-
late our results. Certainly visceral ischemia-reperfusion sequela and
multisystem organ failure with a supraceliac clamp are known to be
greater with a supracelaic clamp than a suprarenal or infrarenal
clamping. In addition, with the known coagulopathy that develops
from a supraceliac clamp, this also poses problems, and particularly,
we had two patients in this study die of bleeding complications
who had a supraceliac clamp.
As far as blood loss, we did not actually measure the blood loss.
It is difficult at our institution to give a precise amount of blood
loss with the cell saver used, so this is why we used units of packed
red blood cells transfused.
In addition, looking at the intraoperative variables, I did not
review the anesthetic variables, so it is difficult for me to speculate
on whether there were fluctuations within blood pressure upon
release of clamps. I can just point out at that point that we did not
have any intraoperative deaths or immediately postoperative
deaths; and so, if there was difficulty, we would have really seen that
much earlier on.
As for using the retroperitoneal versus transabdominal ap-
proach, my personal preference is a retroperitoneal exposure. Some
of this depends on the iliac anatomy and whether concomitant
renal revascularization is needed. In any event, because we are a
teaching institution, we use both to allow our residents equal
exposure to both approaches. If we use a transabdominal exposure
for a suprarenal clamp, we more routinely mobilize the renal vein in
its entire length, dividing the adrenal vein and gonadal vein and
possibly the lumbar vein to allow us more proximal exposure.
Exposure of the supraceliac aorta through the transabdominal
approach is routine. If we use the retroperitoneal approach, fre-
quently we will remove the eleventh rib and divide the left crus of
the diaphragm for both suprarenal and supraceliac clamping.
And the last question regarded using endovascular repair for
these approaches. Our group has a small experience with staged
visceral bypasses prior to excluding thoracoabdominal aneurysms
from dissections but used that technique for routine juxtarenal
aneurysm repair.
Dr Karl A. Illig (Rochester, NY). I definitely enjoyed your
talk, Tim, and it is always helpful to hear results of a nice big series
like yours. As you very charitably discussed, we have extensive
experience with this in Rochester, and as you know, we believe that
a nice elective supraceliac clamp is a wonderful thing. Where we
have run into problems is when an initially suprarenal clamp has to
be shifted to a higher level because of intraoperative problems.
Have you had this experience in your series? And if so, which group
are you assigning them to in your paper?
Dr Sarac. Ten percent of the patients in this series were
symptomatic patients. One patient out of 138 did have an infrare-
nal clamp, which was abandoned for a supraceliac clamp in the
series, and that patient ended up getting multiple intestinal infarcts
from massive embolization and expired. So, we did have just one
patient with a clamp reposition in our series. Removing this patient
from analyses would not have changed the results or conclusions of
this study.
Dr Gary A. Fantini (New York, NY). We reported our much
more modest experience with this problem at this meeting several
years ago (Vasc Surg 2000;34:25-32).
My question revolves around patterns of atherosclerosis of the
suprarenal and supraceliac aorta. May the clamp level in this study
simply have been a surrogate marker for more severe disease at the
suprarenal level such that it precluded clamp placement at that
level? Similarly, may some of these patients have had an unsuccess-
ful attempt at suprarenal clamping, such that an embolic event may
have been created or a plaque fractured, prior to eventual clamp
placement at the supraceliac level? In my experience, the suprace-
liac position is a safe and generally favorable place to occlude the
abdominal aorta.
Dr Sarac. Regarding your first comment, I think both as you
and Dr Ricotta have stated, there is no doubt that this is a marker
for more extensive atherosclerotic disease, meaning the patients
who we clamped supraceliac were certainly more likely to have a
diseased aorta, whether it be atherosclerotic or thrombotic, in the
perivisceral segment. And that is the reason that they were clamped
supraceliac. However, the corollary is, and one of the main points
we are bringing out is that a vast majority of the patients can be
clamped suprarenal, and this determination is augmented with
appropriate imaging. We can now identify most of the patients who
we can avoid supraceliac clamping and therefore avoid the poten-
tial deleterious effects of visceral ischemia/reperfusion, emboliza-
tion, and coagulopathies. Again, only one of the patients in this
report had their clamp repositioned from an infrarenal to a suprace-
liac position, and this patient had problems.
In a retrospective study, it is difficult to compare, to say that
everybody should have supraceliac clamp or suprarenal clamp
when you really cannot say that. Some patients were ineligible for
a suprarenal clamp because of atherosclerosis or thrombus or renal
arteries too close to the superior mesenteric artery to safely place a
clamp. Most of these patients were identified preoperatively with
improved imaging studies. The important point that comes out is
that if you can, if the preoperative CAT scan or the preoperative
angiogram shows you that you can put a clamp in that area safely,
our data support the San Francisco experience that the patients do
better.
Dr Richard P. Cambria (Boston, Mass). Tim, it was a nice
series and no one could argue with the results. I agree with Dr
Ricotta’s comments, with only eight deaths, the statistical message
may be a bit skewed. However, if we believe the message that a
supravisceral clamp was clearly associated with a worse outcome,
what are your thoughts or could you comment on a compromised
position? When one is approaching these aneurysms from the
lateral approach, you can pick and choose where that clamp might
want to go.
And my question is, given what you have discovered about the
apparent impact of a supravisceral clamp location, would you
explore the possibility of putting the clamp between the celiac and
the superior mesenteric, which is certainly a possibility in many
patients, particularly if one is in from a lateral approach?
And my second question is, you may have mentioned it in your
presentation, but what was the percentage of these patients who
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had some concomitant renovascular reconstruction at the time of
their aneurysm repair?
Dr Sarac. The question regarding whether I would advocate
placing a clamp between the supraceliac and superior mesenteric
artery, I think that every patient is different and you have to use
your judgment with each case. Certainly if there is a long distance
of 3 to 4 cm so that it is a chip shot and you can put it between the
SMA and celiac artery and you cannot safely clamp at the suprare-
nal level, I think it would be wise to put it there and continue
visceral perfusion. However, the number of instances that that is
available in my experience is infrequent.
Concerning concommitant renal revascularization, 35% of the
patients in the supravisceral group actually underwent a concomi-
tant renal artery revascularization compared with 23% in the supra-
renal group. And although those numbers did not reach statistical
significance, I think that that may have—all this is anecdotal—a
type II error here—but I think that that certainly contributed to
the increased incidence of renal insufficiency in conjunction with
other factors.
Dr Bruce J. Brener (Millburn, NJ). Do you use adjuncts like
pharmacologic manipulation, renal perfusion, or cooling?
Dr Sarac. Typically, if we are anticipating a prolonged clamp
time or for suprarenal aneurysms or thoracoabdominal aneurysms,
we will use the cooling solution that has previously been described.
In this series, it is variable, and I could not pick out of the data
which of the patients had it and which of the patients did not. It
was sparsely mentioned in operative reports and it is more used at
the surgeon’s discretion.
However, our general approach is that if we are anticipating
doing a renal artery bypass or a prolonged clamp time, we tend to
use a renal artery cooling with perfusate. Our anesthetic regimen
for intraoperative mannitol, vasodilatation, fluids, and postopera-
tive dopamine are routine in our institution.
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